T cell immunity to tumor antigens

Critical Reviews in Immunology

Volumn 18, Issue 1-2, 1997, Pages 1-6

  Hellström, Ingegerd ^a   Hellström, Karl Erik ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELLULAR IMMUNITY; CONFERENCE PAPER; HELPER CELL; HOST RESISTANCE; HUMAN; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINE PRODUCTION; ARTICLE; IMMUNITY; IMMUNOLOGY; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; HUMANS; IMMUNITY; T-LYMPHOCYTES;

EID: 0030660197     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Hellström, K. E., Hellström, I., and Chen, L., Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev., 145, 123, 1995.
2. Hellström, K. E., Hellström, I., and Chen, L., Antitumor vaccines, in New Generation Vaccines, Levine, M. M., et al., Eds., Marcel Dekker, New York, NY, 1997, in press.
3. Hellström, I. and Hellström, K. E., Tumor vaccines - a reality at last? J. Biol. Ther., 1997, in press.
4. Hellström, K. E. and Hellström, I., Tumor vaccines, in Handbook of Experimental Pharmacology, Perlmann, P. and Wigzell, H., Eds., Springer Verlag, Heidelberg, in press.
5. Hellström, K. and Hellström, I., Cellular immunity against tumor specific antigens, Adv. Canc. Res., 12, 167, 1969.
6. Boon, T., et al., Tumor antigens recognized by T lymphocytes, Annu. Rev. Immunol., 12, 337, 1994.
7. Melief, C. and Käst, W., T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes, Immunol. Rev., 145, 167, 1995.
8. Greenberg, P. D., Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells, Adv. Immunol., 49, 281, 1991.
9. Chen, L., et al., Human papillomavirus type 16 nucleo-protein is a tumor rejection antigen, Proc. Natl. Acad. Sci. U.S.A., 88, 110, 1991.
10. Cheever, M., et al., Immunity to oncogenic proteins, Immunol. Rev., 145, 33, 1995.
11. Melief, C. J. M., T-cell immunity against tumors, a delicate balancing act, Crit. Rev. Immunol., in press.
12. Kast, W. M., et al., Peptide-based tumor vaccines: friends or foes? Crit. Rev. Immunol., 1997, in press.
13. DeLeo, A. B., Wild type-sequence p53 epitope-based immunotherapy, Crit. Rev. Immunol., 1997, in press.
14. Knuth, A. and Jager, E., Immune responses to melanoma associated antigens, Crit. Rev. Immunol., 1997, in press.
15. Finn, O. J., et al., MUC-1 epithelial tumor mucin-based immunity and cancer vaccines, Immunol. Rev., 145, 61, 1995.
16. Hellström, K. E. and Hellström, I., Oncogene-associated tumor antigens as targets for immunotherapy, FASEB J., 3, 1715, 1989.
17. Yeh, M.-Y., Hellström, I., and Hellström, K. E., Clonal variation in expression of a homan melanoma antigen defined by a monoclonal antibody, J. Immunol., 126, 1312, 1981.
18. Albino, A. P., et al., Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens, Proc. Natl. Acad. Sci. U.S.A., 154, 1764, 1981.
19. Garrido, F., et al., Implications for immunosurveillance of altered HLA class I phenotypes in human tumors, Immunol. Today, 18, 89, 1997.
20. Ferrone, S. and Marincola, F. M., Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance, Immunol. Today, 16, 487, 1995.
21. Hellström, I., Gladstone, P., and Hellström, K., Cancer vaccines: challenges and potential solutions, Molec. Med. Today, 3, 286, 1997.
22. Porgador, A., et al., Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases, Cancer Res., 55, 4941, 1995.
23. Sjögren, H. O., Studies on specific transplantation resistance to tumors. IV. Stability of the polyoma tumor cell antigen, J. Natl. Cancer Inst., 32, 661, 1964.
24. Klein, E., Klein, G., and Hellström, K. E., Further studies on isoantigenic variation in mouse carcinomas and sarcomas, J. Natl. Cancer Inst., 25, 271, 1960.
25. Chen, L., et al., Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4, Cell 71, 1093, 1992.
26. Townsend, S. E., et al., Specificity and longevity of antitumor immune responses induced by B7-transfected tumors, Cancer Res., 54, 6477, 1994.
27. Yang, G., et al., in-negative vs. B7 positive P815 tumor: differential requirements for priming of an anti-tumor immune response in lymph nodes, J. Immunol., 158, 851, 1997.
28. Chen, L., et al., Tumor immunogenicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity, J. Exp. Med., 179, 523, 1994.
29. Li, Y., et al., Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors, J. Exp. Med., 183, 639, 1996.
30. Johnston, J., et al., B7-CD28 Costimulation unveils the hierarchy of tumor epitopes recognized by MHC class I-restricted CD8+ cytolytic T lymphocytes, J. Exp. Med., 183, 791, 1996.
31. Pollok, K. E., Kim, S. H., and Kwon, B. S., Regulation of 4-1BB expression by cell-cell interactions and cytokines, Interleukin-2 and Interleukin-4, Eur. J. Immunol., 25, 488, 1995.
32. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses, J. Exp. Med., 1997, in press.
33. Smith, C. A., Farrah, T., and Goodwin, R. G., The TNF receptor superfamily of cellular and viral proteins: activation, Costimulation, and death, Cell, 76, 959, 1994.
34. Goodwin, R. G., et al., Molecular cloning a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor, Eur. J. Immunol., 23, 2631, 1993.
35. Alderson, M. E., et al., Molecular and biological characterization of human 4-1BB and its ligand, Eur. J. Immunol., 24, 2219, 1994.
36. Melero, I., et al., Anti 4-1BB monoclonal antibodies activate T cells and eradicate established tumors, Nature Med., 1997.
37. Melero, I., et al., Amplification of cytolytic T lymphocyte-mediated tumor immunity by expression of the costimulatory 4-1BB ligand on tumors: requirement for and synergy with the CD28 costimulatory pathway, 3, 682, 1997.
38. Allison, J., et al., Costimulatory and inhibitory aspects of T cell activation and their manipulation in tumor immunotherapy, Crit. Rev. Immunol., 1997, in press.
39. Lynch, D. H., et al., Flt3 ligand: A dendritic cell-stimulating cytokine that induces tumor regression and anti-tumor immune responses in vivo, Crit. Rev. Immunol., 1997, in press.
40. Pardoll, D. M., Paracrine cytokine adjuvants in cancer immunotherapy, Annu. Rev. Immunol., 13, 399, 1995.
41. Rubin, M., Kamoun, M., and Trinchieri, G., Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells, J. Exp. Med., 180, 211, 1994.
42. Hsu, F. J., et al., Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells, Nature Med., 2, 52, 1996.
43. Gershon, R. K., Carter, R. L., and Kondo, K., On concomitant tumor immunity in tumor-bearing ham sters, Nature (London) 213, 674, 1985.
44. Southam, C. M., Evidence for cancer-specific antigens in man, Prog. Exp. Tumor Res., 9, 1, 1967.
45. Sulitzeanu, D., Immunosuppressive factors in human cancer, Adv. Cancer Res., 60, 247, 1993.
46. Mai, D. and Niederkorn, J. Y., Transforming growth factor-beta down-regulates major histocompatibility eomplex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis, Immunology, 86, 263, 1995.
47. Hahne, M., et al., Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape, Science, 274, 1363, 1996.
48. Himmelweit, B., Ed., The Collected Papers of Paul Ehrlich, Pergamon Press, Oxford, England, 1957.
49. Coley, W., Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases, Bull. Johns Hopkins Hosp., 7, 157, 1896.
50. Rosenberg, S. A., Cell transfer therapy: clinical applications, in Biologic Therapy of Cancer, Second Edition, DeVita, V. T., Hellman, S., and Rosenberg, S. A., Eds., J. P. Lippincott, Philadelphia, PA, 1995, 487.
51. Livingston, P. O., et al., Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside, J. Clin. Oncol., 12, 1036, 1994.